USDL chief predicts more buyouts by fast-growing center company

Article

Company contemplates possible ISO acquisitionA high-ranking U.S. Diagnostic executive predicts that the explosivegrowth that propelled his company from obscurity to market leadershipin the imaging services industry will continue through next

Company contemplates possible ISO acquisition

A high-ranking U.S. Diagnostic executive predicts that the explosivegrowth that propelled his company from obscurity to market leadershipin the imaging services industry will continue through next year.

USDL president and COO Joseph Paul said that, if examined ona pro forma basis (also called run rate), USDL would ring up morethan $200 million in revenue this year, providing the performanceof all its properties were considered. In reality, revenues willbe close to $110 million.

This performance almost guarantees that USDL will soon surpassHealth Images as the nation's largest imaging services provider,according to Paul. By the end of 1997, the company could own morethan 150 centers.

"The pace we've generated is not going to slow down. It'sgoing to continue, if not increase," he said.

USDL's acquisitive ways continued in October, with two newdeals adding five more imaging centers to the West Palm Beach,FL, company.

On Oct. 24, USDL secured a definitive agreement to acquirefive multimodality outpatient diagnostic imaging centers fromDayton Medical Imaging in Dayton, OH. The five facilities, locatedin and around Dayton, will generate about $12 million in salesand $4.5 million in pre-tax income this year, according to thecompany.

The Dayton deal was announced three days after USDL boughtthree facilities in the boroughs and suburbs of New York. Themultimodality services are Gramercy MRI in New York City, NarrowsMRI in Brooklyn, and Metropolitan Imaging in Garden City, NY.Their combined revenues will be about $6 million this year.

From March to up until these deals were made, USDL had grownfrom 17 centers to 61. The industry began to seriously take noteof the company in June, when it edged out Diagnostic Imaging Servicesof Los Angeles with a successful last-minute bid for San Diego-basedMedical Imaging Centers of America (SCAN 7/31/96). If stockholdersapprove that takeover this week as expected, USDL will grow byanother 17 fixed and six fee-for-scan sites. USDL has also announcedthe acquisition of three more centers in San Antonio, TX, whichwill raise its total to 87 centers.

After the $36 million MICA deal closes, the company will stillhave $46 million available for more acquisitions, Paul said. Thatsum excludes another $15 million in untapped bank credit thatcould be used to fuel growth, he noted.

USDL's immediate plans call for additional centers to add tothe firm's existing market concentrations in Houston, San Antonio,Jacksonville, FL, and southern California, Paul said.

Also on the plate is a possible acquisition of an independentservice organization. USDL maintains about a quarter of its multimodalityequipment inventory on an in-house basis, Paul said. As the companygrows, he would not be surprised if USDL bought a regional orsubregional ISO, he said.

Recent Videos
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Related Content
© 2025 MJH Life Sciences

All rights reserved.